Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults. Commercial arrangement There is a simple discount patient access scheme for vutrisiran. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NH...

Texte intégral